Molecular MR Imaging of Prostate Cancer

Biomedicines. 2020 Dec 22;9(1):1. doi: 10.3390/biomedicines9010001.


This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.

Keywords: magnetic resonance imaging; molecular imaging; molecular marker; prostate cancer.

Publication types

  • Review